Senate 340B Discussion Draft Surfaces on the Cassidy/HELP Track — a Mirror Image of SUSTAIN on the Contested Pillars
What it is. The document names no sponsor on its face (the “S.L.C.” marking signals a Senate Legislative Counsel draft). Substantively it tracks Chair Bill Cassidy’s (R-LA) April 2025 HELP Committee report reform pillars — a statutory patient definition, mandatory direct patient savings, margin transparency, and middleman fee caps — and it is structurally near-identical to the House 340B ACCESS Act (H.R. 5256) on contract pharmacies, child sites, affordability, and third-party fees. Read it as the Senate companion to that manufacturer-aligned framework. It is a different animal from the bipartisan SUSTAIN 340B Act, whose introduction has stalled amid the rebate-model fight. The two drafts now mark the poles of the Senate debate.
The three contested pillars, side by side:
Patient definition
SUSTAIN 340B : Placeholder. Solicits a definition from stakeholders rather than imposing one — the Working Group is still negotiating it.
Cassidy / ACCESS : Imposes a hard test: a billable outpatient service at the entity within 2 years, an auditable record, and an Rx tied to that service or a qualifying referral.
Contract Definition
SUSTAIN 340B : Formalizes CP arrangements in statute and penalizes manufacturers that restrict access — a pro-access posture akin to Arkansas Act 1103 and the 340B PATIENTS Act.
Cassidy / ACCESS : Restricts access: a 5-pharmacy cap for DSH, free-standing cancer, and rural referral centers; CPs confined to the entity’s PUMA service area; mail-order limits.
Hospital child access :
SUSTAIN 340B : Clarifies eligibility and anchors it to existing Medicare provider-based rules.
Cassidy / ACCESS : Adds disqualifying screens on top of provider-based status: HPSA location, plus charity-care and Medicaid-share floors benchmarked to the greater of on-campus or statewide — with retroactive deregistration.
Direction of travel. The contract pharmacy contrast is the headline. SUSTAIN would codify CP access and put manufacturers on the hook for restricting it; this draft would cap and geo-fence it. For a DSH system the operative number is five — a hard ceiling on third-party contract pharmacies that would strand most existing networks, with relief only for wholly owned “entity pharmacies” inside the service area. The PUMA limit compounds it: contract pharmacies must sit in the entity’s Public Use Microdata Area or a contiguous one, which national-chain and mail arrangements cannot satisfy. Community health center advocates have already flagged that the PUMA construct loosely overlaps but does not match HRSA grant service areas and hits rural entities hardest — a critique that applies with equal force to rural and exurban hospital sites.
On the patient definition, SUSTAIN’s placeholder is a feature, not an omission — the Working Group is still negotiating it. This draft makes the call, and makes it tight: the two-year lookback, the requirement that the encounter be a billable outpatient service, and the record/audit conditions together narrow the eligible-fill universe and push compliance risk onto the entity at the point of dispense.
On child sites, both drafts answer the same CBO finding — that hospital–clinic integration is the single largest driver of program growth. But where SUSTAIN tightens by anchoring to provider-based rules, this draft layers HPSA-location, charity-care, and Medicaid-share tests on top, benchmarked against a moving target, and forces deregistration of sites that miss. That is the provision most likely to disqualify suburban and exurban outpatient sites and to unwind investments made under current rules.
Beyond the three pillars. Three escalations have no real analog in SUSTAIN. First, the draft codifies the manufacturer rebate model as an explicit manufacturer election — the same WAC-up-front, rebate-on-the-back-end mechanic now working through the HRSA pilot and the courts, but written into statute and at the manufacturer’s option. Second, it imposes a patient-affordability pass-through: hospital entities would run a sliding scale capping out-of-pocket for uninsured and sub-200%-FPL insured patients on every covered drug, with income verification at the counter. Third, it caps TPA and contract pharmacy fees (CP dispensing fees at 125% of the average third-party rate) under a steep penalty regime — the lone area where the draft’s instinct overlaps with provider complaints about middleman fees, even as the mechanism is blunt.
Prospects and the planning read. Near-term legislative odds are low. Observers now expect no major congressional 340B action in 2026, and SUSTAIN — the more likely vehicle — is stuck. The value of this draft is as a signal: it shows where Senate Republican reform lands once the placeholders are filled in, and it leans decisively manufacturer-ward on every contested pillar. The live battlegrounds for the next twelve months remain the HRSA rebate pilot, contract-pharmacy litigation, and the state access-law front, not the Senate floor. For health-system pharmacy leadership the takeaways are concrete: model a five-pharmacy contract ceiling and a PUMA-bounded network as a downside scenario; pressure-test which child sites would survive an HPSA-plus-charity-care-plus-Medicaid screen; and treat the rebate model as the near-term threat regardless of whether this draft moves.
